These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 15930303)

  • 1. A novel peptide specifically binding to interleukin-6 receptor (gp80) inhibits angiogenesis and tumor growth.
    Su JL; Lai KP; Chen CA; Yang CY; Chen PS; Chang CC; Chou CH; Hu CL; Kuo ML; Hsieh CY; Wei LH
    Cancer Res; 2005 Jun; 65(11):4827-35. PubMed ID: 15930303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivo growth of human oral squamous cell carcinoma.
    Shinriki S; Jono H; Ota K; Ueda M; Kudo M; Ota T; Oike Y; Endo M; Ibusuki M; Hiraki A; Nakayama H; Yoshitake Y; Shinohara M; Ando Y
    Clin Cancer Res; 2009 Sep; 15(17):5426-34. PubMed ID: 19706815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis.
    Bae DG; Kim TD; Li G; Yoon WH; Chae CB
    Clin Cancer Res; 2005 Apr; 11(7):2651-61. PubMed ID: 15814646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
    Gacche RN; Meshram RJ
    Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
    Sun J; Blaskovich MA; Jain RK; Delarue F; Paris D; Brem S; Wotoczek-Obadia M; Lin Q; Coppola D; Choi K; Mullan M; Hamilton AD; Sebti SM
    Cancer Res; 2004 May; 64(10):3586-92. PubMed ID: 15150116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A KDR-binding peptide (ST100,059) can block angiogenesis, melanoma tumor growth and metastasis in vitro and in vivo.
    Rastelli L; Valentino ML; Minderman MC; Landin J; Malyankar UM; Lescoe MK; Kitson R; Brunson K; Souan L; Forenza S; Goldfarb RH; Rabbani SA
    Int J Oncol; 2011 Aug; 39(2):401-8. PubMed ID: 21567086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways.
    Xu Q; Briggs J; Park S; Niu G; Kortylewski M; Zhang S; Gritsko T; Turkson J; Kay H; Semenza GL; Cheng JQ; Jove R; Yu H
    Oncogene; 2005 Aug; 24(36):5552-60. PubMed ID: 16007214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A hybrid protein comprising ATF domain of pro-UK and VAS, an angiogenesis inhibitor, is a potent candidate for targeted cancer therapy.
    Sun Q; Xu Q; Dong X; Cao L; Huang X; Hu Q; Hua ZC
    Int J Cancer; 2008 Aug; 123(4):942-50. PubMed ID: 18528863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist.
    Kumar CC; Malkowski M; Yin Z; Tanghetti E; Yaremko B; Nechuta T; Varner J; Liu M; Smith EM; Neustadt B; Presta M; Armstrong L
    Cancer Res; 2001 Mar; 61(5):2232-8. PubMed ID: 11280792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
    Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
    Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.
    Tassone P; Neri P; Burger R; Savino R; Shammas M; Catley L; Podar K; Chauhan D; Masciari S; Gozzini A; Tagliaferri P; Venuta S; Munshi NC; Anderson KC
    Clin Cancer Res; 2005 Jun; 11(11):4251-8. PubMed ID: 15930364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual-function synthetic peptide derived from BMP4 for highly efficient tumor targeting and antiangiogenesis.
    Choi SH; Lee JY; Suh JS; Park YS; Chung CP; Park YJ
    Int J Nanomedicine; 2016; 11():4643-4656. PubMed ID: 27695323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
    Huang SW; Lien JC; Kuo SC; Huang TF
    Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects.
    Abdollahi A; Lipson KE; Sckell A; Zieher H; Klenke F; Poerschke D; Roth A; Han X; Krix M; Bischof M; Hahnfeldt P; Grone HJ; Debus J; Hlatky L; Huber PE
    Cancer Res; 2003 Dec; 63(24):8890-8. PubMed ID: 14695206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiangiogenic targeting liposomes increase therapeutic efficacy for solid tumors.
    Chang DK; Chiu CY; Kuo SY; Lin WC; Lo A; Wang YP; Li PC; Wu HC
    J Biol Chem; 2009 May; 284(19):12905-16. PubMed ID: 19276080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of the antiangiogenic activity of interleukin-12 by peptide targeted delivery of the cytokine to alphavbeta3 integrin.
    Dickerson EB; Akhtar N; Steinberg H; Wang ZY; Lindstrom MJ; Padilla ML; Auerbach R; Helfand SC
    Mol Cancer Res; 2004 Dec; 2(12):663-73. PubMed ID: 15634755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo.
    Cao ZX; Zheng RL; Lin HJ; Luo SD; Zhou Y; Xu YZ; Zeng XX; Wang Z; Zhou LN; Mao YQ; Yang L; Wei YQ; Yu LT; Yang SY; Zhao YL
    Cell Physiol Biochem; 2011; 27(5):565-74. PubMed ID: 21691074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of Potent Anti-Vascular Endothelial Growth Factor Neutralizing Antibodies from Mouse Phage Display Library for Cancer Therapy.
    Lai YD; Wu YY; Tsai YJ; Tsai YS; Lin YY; Lai SL; Huang CY; Lok YY; Hu CY; Lai JS
    Int J Mol Sci; 2016 Feb; 17(2):214. PubMed ID: 26861297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting of tumor blood vessels: a phage-displayed tumor-homing peptide specifically binds to matrix metalloproteinase-2-processed collagen IV and blocks angiogenesis in vivo.
    Mueller J; Gaertner FC; Blechert B; Janssen KP; Essler M
    Mol Cancer Res; 2009 Jul; 7(7):1078-85. PubMed ID: 19584266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pien Tze Huang inhibits tumor angiogenesis in a mouse model of colorectal cancer via suppression of multiple cellular pathways.
    Shen A; Lin J; Chen Y; Lin W; Liu L; Hong Z; Sferra TJ; Peng J
    Oncol Rep; 2013 Oct; 30(4):1701-6. PubMed ID: 23843018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.